Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging

被引:425
作者
Mulder, WJM
Strijkers, GJ
van Tilborg, GAF
Griffioen, AW
Nicolay, K
机构
[1] Eindhoven Univ Technol, Dept Biomed Engn, Biomed NMR, NL-5600 MB Eindhoven, Netherlands
[2] Maastricht Univ, Dept Pathol, Res Inst Growth & Dev, Angiogenesis Lab, NL-6202 AZ Maastricht, Netherlands
[3] Univ Hosp, NL-6202 AZ Maastricht, Netherlands
关键词
lipid-based nanoparticles; contrast-enhanced magnetic resonance imaging; molecular imaging; micelles; liposomes; microemulsions;
D O I
10.1002/nbm.1011
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
In the field of MR imaging and especially in the emerging field of cellular and molecular MR imaging, flexible strategies to synthesize contrast agents that can be manipulated in terms of size and composition and that can be easily conjugated with targeting ligands are required. Furthermore, the relaxivity of the contrast agents, especially for molecular imaging applications, should be very high to deal with the low sensitivity of MRI. Lipid-based nanoparticles, such as liposomes or micelles, have been used extensively in recent decades as drug carrier vehicles. A relatively new and promising application of lipidic nanciparticles is their use as multimodal MR contrast agents. Lipids are amphiphilic molecules with both a hydrophobic and a hydrophilic part, which spontaneously assemble into aggregates in an aqueous environment. In these aggregates, the amphiphiles are arranged such that the hydrophobic parts cluster together and the hydrophilic parts face the water. In the low concentration regime, a wide variety of structures can be formed, ranging from spherical micelles to disks or liposomes. Furthermore, a monolayer of lipids can serve as a shell to enclose a hydrophobic core. Hydrophobic iron oxide particles, quantum dots or perfluorocarbon emulsions can be solubilized using this approach. MR-detectable and fluorescent amphiphilic molecules can easily be incorporated in lipidic nanoparticles. Furthermore, targeting ligands can be conjugated to lipidic particles by incorporating lipids with a functional moiety to allow a specific interaction with molecular markers and to achieve accumulation of the particles at disease sites. In this review, an overview of different lipidic nanoparticles for use in MRI is given, with the main emphasis on Gd-based contrast agents. The mechanisms of particle formation, conjugation strategies and applications in the field of contrast-enhanced, cellular and molecular MRI are discussed. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:142 / 164
页数:23
相关论文
共 184 条
[51]   Thermosensitive paramagnetic liposomes for temperature control during MR imaging-guided hyperthermia: In vitro feasibility studies [J].
Fossheim, SL ;
Il'yasov, KA ;
Hennig, J ;
Bjornerud, A .
ACADEMIC RADIOLOGY, 2000, 7 (12) :1107-1115
[52]   Paramagnetic liposomes as MRI contrast agents: Influence of liposomal physicochemical properties on the in vitro relaxivity [J].
Fossheim, SL ;
Fahlvik, AK ;
Klaveness, J ;
Muller, RN .
MAGNETIC RESONANCE IMAGING, 1999, 17 (01) :83-89
[53]   Recombinant HDL-like nanoparticles: A specific contrast agent for MRI of atherosclerotic plaques [J].
Frias, JC ;
Williams, KJ ;
Fisher, EA ;
Fayad, ZA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (50) :16316-16317
[54]   Experimental application of thermosensitive paramagnetic liposomes for monitoring magnetic resonance imaging guided thermal ablation [J].
Frich, L ;
Bjornerud, A ;
Fossheim, S ;
Tillung, T ;
Gladhaug, I .
MAGNETIC RESONANCE IN MEDICINE, 2004, 52 (06) :1302-1309
[55]   Atherosclerosis: The road ahead [J].
Glass, CK ;
Witztum, JL .
CELL, 2001, 104 (04) :503-516
[56]   Novel radical-responsive MRI contrast agent based on paramagnetic liposomes [J].
Glogård, C ;
Stensrud, G ;
Aime, S .
MAGNETIC RESONANCE IN CHEMISTRY, 2003, 41 (08) :585-588
[57]   Liposomes as carriers of amphiphilic gadolinium chelates:: the effect of membrane composition on incorporation efficacy and in vitro relaxivity [J].
Glogård, C ;
Stensrud, G ;
Hovland, R ;
Fossheim, SL ;
Klaveness, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 233 (1-2) :131-140
[58]  
Griffioen AW, 2000, PHARMACOL REV, V52, P237
[59]   CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells [J].
Griffioen, AW ;
Coenen, MJH ;
Damen, CA ;
Hellwig, SMM ;
vanWeering, DHJ ;
Vooys, W ;
Blijham, GH ;
Groenewegen, G .
BLOOD, 1997, 90 (03) :1150-1159
[60]  
Haacke EM, 1999, MAGNETIC RESONANCE I